Tumour necrosis factor (TNF) inhibitors, which are the first type of bDMARDs approved for the treatment of RA, are still used as the first line of bDMARDs for patients with RA with an inadequate response to methotrexate (MTX-IR) because of their confirmed long-term efficacy and safety.3 This evidence concerns the gene TNF and rheumatoid arthritis.